3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
5
Breast Neoplasms
3
Neoplasm Metastasis
2
Leukemia, B-Cell
2
Urinary Bladder Neoplasms
1
Polycystic Ovary Syndrome
1
Parathyroid Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Leukemia
1
Hyperparathyroidism, Primary
1
Head and Neck Neoplasms
1
Diabetes Mellitus
1
Carcinoma, Renal Cell
1
Carcinoma
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Sorafenib
52
pembrolizumab
26
Nivolumab
20
Bevacizumab
19
Radiosurgery
17
Doxorubicin
12
atezolizumab
9
Erlotinib Hydrochloride
9
lenvatinib
8
cabozantinib
7
Magnetic Resonance Spectroscopy
7
tremelimumab
6
durvalumab
6
Ramucirumab
6
Radiofrequency Ablation
6
Cisplatin
6
Sunitinib
5
tislelizumab
4
regorafenib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorouracil
4
Everolimus
4
Capecitabine
4
nintedanib
3
fluoromisonidazole
3
carotuximab
3
bavituximab
3
Tomography, X-Ray Computed
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Hepatocellular
×
Tablets
×
Clear all
No trials found.